High expression of Midkine (MK) indicates poor prognosis in childhood acute lymphoblastic leukemia

Hematology
M JiaYong-Min Tang

Abstract

Midkine (MK) expression has been reported to be correlated with the poor prognosis of patients with various tumors. However, there are no data available about the prognostic value of MK expression in childhood acute lymphoblastic leukemia (ALL). In this study, MK mRNA expression was determined by real-time polymerase chain reaction in 120 childhood ALL and 30 healthy volunteers. Patients were dichotomized at the median value and divided into two groups: MK(low) group and MK(high) group. MK(high) patients had higher white blood cell counts, higher peripheral blood blasts percentages, and higher minimal residual disease levels than MK(low) patients. Moreover, the MK gene was expressed significantly higher in patients with relapsed ALL than in patients who maintained complete remission or at diagnosis. MK(high) patients harbored inferior relapse-free survival (RFS, P = 0.047) and overall survival (OS, P = 0.022) than MK(low) patients, and high expression of MK was found to be independently predictive of inferior OS (P = 0.032) but not RFS (P = 0.077) in the overall cohort. MK high expression is an independent adverse prognostic factor in childhood ALL. Its level may be incorporated into an improved risk classification system for A...Continue Reading

References

Jun 14, 1991·Biochemical and Biophysical Research Communications·H Muramatsu, T Muramatsu
Apr 21, 1995·The Journal of Biological Chemistry·S KojimaT Muramatsu
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M SmithR Ungerleider
Jan 1, 1997·British Journal of Cancer·K KadomatsuT Muramatsu
Aug 23, 2000·British Journal of Cancer·S IkematsuT Muramatsu
Sep 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·W SatoT Muramatsu
Jan 22, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hio Chung KangJae-Gahb Park
Feb 3, 2007·Leukemia Research·Hirokazu HidakaSeiji Kojima
Apr 15, 2008·Nature·Charles G MullighanJames R Downing
May 29, 2008·Pediatric Blood & Cancer·Yongmin TangJian Wei
Dec 23, 2008·Seminars in Hematology·Martin Stanulla, Martin Schrappe
Oct 15, 2009·Hematology/oncology Clinics of North America·Sima Jeha, Ching-Hon Pui
Jun 8, 2010·Journal of Experimental & Clinical Cancer Research : CR·Gregory E RiceDominic J Autelitano
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiRobert J Arceci
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony V MoormanChristine J Harrison
May 31, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wen-Wei ZhuQing-Hai Ye
Jul 3, 2013·British Journal of Haematology·David T Teachey, Stephen P Hunger
Aug 10, 2013·Cancer Medicine·Daisuke AsaiUNKNOWN Japan Association of Childhood Leukemia Study (JACLS)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.